Trials / Completed
CompletedNCT01850641
A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the safety and efficacy when administering PA21 with calcium carbonate in hemodialysis patients with hyperphosphatemia for 12 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PA21 |
Timeline
- Start date
- 2013-04-29
- Primary completion
- 2013-12-01
- Completion
- 2013-12-03
- First posted
- 2013-05-09
- Last updated
- 2018-10-09
- Results posted
- 2018-10-09
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01850641. Inclusion in this directory is not an endorsement.